🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Innovative medicines have the power to tackle chronic disease. To make that happen, we need America to remain the global home of R&D. And we need to improve patient affordability, too. As I shared on stage at @Semafor’s #WorldEconomySummit, I’m heartened by progress at our

Amgen’s $900M investment to expand its manufacturing presence in Ohio is evidence of the industry’s continued commitment to create economic opportunities for Americans and bring cutting-edge manufacturing capabilities to the United States. Congratulations to the entire Amgen 🧪🔬🧬

Disease doesn’t just affect health—it places a heavy burden on our system and deprives individuals of their potential to live full, vibrant lives. At PhRMA Forum in February, we unveiled our latest innovation report, which explores how medical breakthroughs have transformed

Congratulations to Rob Davis and Merck on the bold $1B investment in U.S. biopharmaceutical manufacturing. This milestone investment in the Delaware Valley shows vision, leadership, and confidence in our industry’s ability to produce even more innovative medicines here in

#PBMreform must remain top of mind for lawmakers – without action, patients will continue to pay the price. In case you missed it, we recently released our 2025 policy agenda, and reining in PBMs’ abusive practices remains a top priority for a healthier America. Read more about

To lower costs for Americans, we need to address the real reasons U.S. prices are higher: foreign countries not paying their fair share and middlemen driving up prices for U.S. patients. Read my full statement on today's announcement from the White House: phrma.org/resources/phrm…

Congratulations to GSK's Emma Walmsley, Novartis's Vas Narasimhan and Eli Lilly and Company's David Ricks for being recognized on the #Time100Health list this year. I’m proud to work with these influential leaders who have all made tremendous contributions to our industry as we work

In this blog from PhRMA, we see how the biopharmaceutical industry directly supports millions of jobs and contributes to America's economy. The study shows that our industry contributed more wages, exports, output and GDP per employee annually from 2012-2022 than the average of

Under the IRA, patients are paying more, not less for prescription drugs. A new Pioneer Institute analysis shows a 32% hike in out-of-pocket costs for seniors for drugs subject to IRA price setting. pioneerinstitute.org/the-inflation-…

Today, researchers from our member companies met with lawmakers on Capitol Hill to advocate for policies that protect biopharmaceutical innovation and ensure patients can access the treatments they need to live healthier lives. We’re proud to support and elevate their voices.

The creativity and leadership of our PRIDE Umbrella, one of our employee resource groups, continually inspires me. Thank you for showing up, pushing for progress, and coordinating events that make our workplace more vibrant and inclusive. Throughout the month of June, PhRMA will

Congratulations to Paul Hudson and the entire @Sanofi team for their continued commitment to investing in America. Their recent announcement to grow their R&D and manufacturing presence in the U.S., along with their new state-of-the-art collaborative workplace in Morristown, NJ,

Congratulations to Chip Kahn on his well-earned retirement after 24 years at the helm of the Federation of American Hospitals. His sharp policy instincts, bipartisan leadership and steady hand during some of the most important health policy debates of our time have left a lasting impression. I’m

Congratulations to Joaquin Duato and the rest of the Johnson & Johnson team for launching their new Center for U.S. Healthcare Policy Research. America's robust, pro-innovation policies and gold-standard biopharmaceutical regulatory system allow it to stand out on the world’s stage. This

UCB’s investment in U.S. biologics manufacturing reflects its growing footprint in the U.S. and ambition to bring its pipeline of innovative medicines to patients. This is a powerful commitment to innovation and patient access that will generate $5B in economic growth. Well done

The #340B program was meant to help patients, not pad hospital profits. But that's exactly what's happening in Ohio and across the country. New reporting adds to growing evidence that nonprofit hospitals exploit 340B markups while vulnerable patients see no benefit. Congress must

The FDA approval of Gilead Sciences new medicine marks a transformative moment in the fight to end the #HIV epidemic. Congratulations to the Gilead team on this milestone. gilead.com/news/news-deta…